Viridian Therapeutics (Viridian Therapeutics) EV-to-EBIT : -2.41 (As of Apr. 26, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Viridian Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Viridian Therapeutics's Enterprise Value is $568.06 Mil. Viridian Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-235.89 Mil. Therefore, Viridian Therapeutics's EV-to-EBIT for today is -2.41.

The historical rank and industry rank for Viridian Therapeutics's EV-to-EBIT or its related term are showing as below:

VRDN' s EV-to-EBIT Range Over the Past 10 Years
Min: -115.37 Med: -1.26 Max: 1.55
Current: -2.41

During the past 12 years, the highest EV-to-EBIT of Viridian Therapeutics was 1.55. The lowest was -115.37. And the median was -1.26.

VRDN's EV-to-EBIT is ranked worse than
100% of 442 companies
in the Biotechnology industry
Industry Median: 8.41 vs VRDN: -2.41

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Viridian Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $926.01 Mil. Viridian Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-235.89 Mil. Viridian Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -25.47%.

Viridian Therapeutics EV-to-EBIT Historical Data

The historical data trend for Viridian Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viridian Therapeutics EV-to-EBIT Chart

Viridian Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

0.04

-1.12

-5.17

-7.18

-3.93

Viridian Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-7.18	-5.02	-4.27	-2.38	-3.93

Competitive Comparison of Viridian Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Viridian Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viridian Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Viridian Therapeutics's EV-to-EBIT falls into.

Viridian Therapeutics EV-to-EBIT Calculation

Viridian Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	568.055	/	-235.887
	=	-2.41

Viridian Therapeutics's current Enterprise Value is $568.06 Mil.
Viridian Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-235.89 Mil.

Viridian Therapeutics (NAS:VRDN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Viridian Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-235.887	/	926.011258
	=	-25.47 %

Viridian Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $926.01 Mil.
Viridian Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-235.89 Mil.

Viridian Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Viridian Therapeutics (Viridian Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (NAS:VRDN) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

1S1:Germany

Address

221 Crescent Street, Suite 401, Waltham, MA, USA, 02453

Website

https://www.viridiantherapeutics.com

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Executives

Stephen F. Mahoney	director, officer: President and CEO	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham	officer: Chief Operating Officer	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Sarah Gheuens	director	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Seth Harmon	officer: See Remarks	C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 401, WALTHAM MA 02453
Lara Meisner	officer: General Counsel and Secretary	C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG. 17, SUITE 102, WALTHAM MA 02453
Scott Dunseth Myers	director, officer: Chief Executive Officer	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Jonathan Violin	officer: President and COO	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Barrett Katz	officer: Chief Medical Officer	6200 LOOKOUT ROAD, C/O MIRAGEN THERAPEUTICS, INC., BOULDER CO 80301
Fairmount Healthcare Fund Gp Llc	director, other: See Remarks	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Carrie Melvin	officer: COO	C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG 17, SUITE 102B, WALTHAM MA 02453
Frazier Life Sciences Public Fund, L.p.	10 percent owner	TWO UNION SQUARE, 601 UNION ST., SUITE 3200, SEATTLE WA 98101
L.p. Fhmlsp,	10 percent owner	C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Fhmlsp, L.l.c.	10 percent owner	C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Kristian Humer	officer: CFO and CBO	C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Jennifer K. Moses	director	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709